366 related articles for article (PubMed ID: 31903155)
1. Therapeutic management of neuro-oncologic patients - potential relevance of CSF liquid biopsy.
von Baumgarten L; Kumbrink J; Jung A; Reischer A; Flach M; Liebmann S; Metzeler KH; Holch JW; Niyazi M; Thon N; Straube A; von Bergwelt-Baildon M; Heinemann V; Kirchner T; Westphalen CB
Theranostics; 2020; 10(2):856-866. PubMed ID: 31903155
[No Abstract] [Full Text] [Related]
2. Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors.
Ronsley R; Karvonen KA; Cole B; Paulson V; Stevens J; Crotty EE; Hauptman J; Lee A; Stasi SM; Lockwood CM; Leary SES
J Neurooncol; 2024 Jun; 168(2):215-224. PubMed ID: 38755519
[TBL] [Abstract][Full Text] [Related]
3. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
4. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
[TBL] [Abstract][Full Text] [Related]
5. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
6. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma.
Yamagishi Y; Sasaki N; Nakano Y; Matushita Y; Omura T; Shimizu S; Saito K; Kobayashi K; Narita Y; Kondo A; Shiokawa Y; Nagane M; Ichimura K
Cancer Sci; 2021 Nov; 112(11):4702-4710. PubMed ID: 34523186
[TBL] [Abstract][Full Text] [Related]
7. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
8. Routine application of next-generation sequencing testing in uro-oncology-Are we ready for the next step of personalised medicine?
Rodler S; Jung A; Greif PA; Rühlmann K; Apfelbeck M; Tamalunas A; Kretschmer A; Schulz GB; Szabados B; Stief C; Heinemann V; Westphalen CB; Casuscelli J
Eur J Cancer; 2021 Mar; 146():1-10. PubMed ID: 33535139
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.
Pagès M; Rotem D; Gydush G; Reed S; Rhoades J; Ha G; Lo C; Fleharty M; Duran M; Jones R; Becker S; Haller M; Sinai CE; Goumnerova L; Golub TR; Love JC; Ligon KL; Wright KD; Adalsteinsson VA; Beroukhim R; Bandopadhayay P
Neuro Oncol; 2022 Aug; 24(8):1352-1363. PubMed ID: 34984433
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
12. Detection of Neoplasms by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid.
Gu W; Rauschecker AM; Hsu E; Zorn KC; Sucu Y; Federman S; Gopez A; Arevalo S; Sample HA; Talevich E; Nguyen ED; Gottschall M; Nourbakhsh B; Gold CA; Cree BAC; Douglas VC; Richie MB; Shah MP; Josephson SA; Gelfand JM; Miller S; Wang L; Tihan T; DeRisi JL; Chiu CY; Wilson MR
JAMA Neurol; 2021 Nov; 78(11):1355-1366. PubMed ID: 34515766
[TBL] [Abstract][Full Text] [Related]
13. Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases.
Angus L; Deger T; Jager A; Martens JWM; de Weerd V; van Heuvel I; van den Bent MJ; Sillevis Smitt PAE; Kros JM; Bindels EMJ; Heitzer E; Sleijfer S; Jongen JLM; Wilting SM
Clin Cancer Res; 2021 May; 27(10):2798-2806. PubMed ID: 33514525
[TBL] [Abstract][Full Text] [Related]
14. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.
Papadopoulou E; Tsoulos N; Tsantikidi K; Metaxa-Mariatou V; Stamou PE; Kladi-Skandali A; Kapeni E; Tsaousis G; Pentheroudakis G; Petrakis D; Lampropoulou DI; Aravantinos G; Varthalitis I; Kesisis G; Boukovinas I; Papakotoulas P; Katirtzoglou N; Athanasiadis E; Stavridi F; Christodoulou C; Koumarianou A; Eralp Y; Nasioulas G
PLoS One; 2019; 14(12):e0226853. PubMed ID: 31860648
[TBL] [Abstract][Full Text] [Related]
15. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
[TBL] [Abstract][Full Text] [Related]
16. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
[TBL] [Abstract][Full Text] [Related]
18. The Utility of Liquid Biopsy in Central Nervous System Malignancies.
Nevel KS; Wilcox JA; Robell LJ; Umemura Y
Curr Oncol Rep; 2018 Jun; 20(8):60. PubMed ID: 29876874
[TBL] [Abstract][Full Text] [Related]
19. The potential of cerebrospinal fluid-based liquid biopsy approaches in CNS tumors.
Mattox AK; Yan H; Bettegowda C
Neuro Oncol; 2019 Dec; 21(12):1509-1518. PubMed ID: 31595305
[TBL] [Abstract][Full Text] [Related]
20. Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients.
Canino F; Tornincasa A; Bettelli S; Manfredini S; Barbolini M; Moscetti L; Omarini C; Toss A; Tamburrano F; Antonelli G; Baglio F; Belluzzi L; Martinelli G; Natalizio S; Ponzoni O; Dominici M; Piacentini F
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]